The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Grant Data
Project Title
The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Principal Investigator
Professor Che, Chi Ming
(Project Coordinator (PC))
Co-Investigator(s)
Dr Lok Chun Nam
(Co-Investigator)
Dr Fung Eva Yi Man
(Co-Investigator)
Dr Wo Henry Lam Kee
(Co-Investigator)
Dr Sy Lai King
(Co-Investigator)
Duration
10
Start Date
2019-03-01
Amount
335000
Conference Title
The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Keywords
Anticancer Effect, Chinese Medicine, Formulation, Olive Branch-1
Discipline
Chinese Medicine (clinical)
Panel
Physical Sciences (P)
HKU Project Code
PiH/037/19
Grant Type
Postdoctoral Hub Programme for ITF projects
Funding Year
2017
Status
Completed
Objectives
Olive Branch-1 (OB-1) is a formulation containing Chinese medicines clinically used for cancer treatment. It has been prescribed by physicians for more than 17 years notably effective for lung, colorectal and lymphatic cancers. The ultimate objective of R&D work of OB-1 is to register and commercialize OB-1 as a proprietary Chinese medicine (pCm) in Hong Kong and other countries for treating cancer. The anticancer effect of OB-1 will primarily be investigated by five major approaches: (a) establish chemical fingerprint and quality evaluation of OB-1 by UPLC-MS-QTOF for identification and quality control; (b) explore the possibility of streamlining the OB-1 formulation without affecting or even enhancing its efficacy; (c) investigate the in vivo effects of OB-1 in animal models; (d) use molecular biology, transcriptomic and proteomic techniques to study the mechanistic action of OB-1 and (e) study the immunomodulatory effects of OB-1. The deliverables brought by the proposed project will steer participating company to make strategic investment on R&D projects including the proposed one. The benefit brought by the project not only on promoting university's and company's technological level but also on giving innovative insights to other Chinese medicine formulations such as OB-2 and OB-3, which have been lined up to be developed.
